List of Contents

Non-Invasive Blood Glucose Monitoring System Market Size, Share, and Trends 2024 to 2034

Non-Invasive Blood Glucose Monitoring System Market (By Technology: Spectroscopy, Electromagnetic, Microwave, Ultrasonic, Thermal, Others; By End User: Hospitals, Homecare, Clinics; By Modality: Non wearable, Wearable, Invasive, Non-invasive; By Distribution Channel: Retail sales, Institutional sales) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2034

  • Last Updated : July 2024
  • Report Code : 2405
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Non-Invasive Blood Glucose Monitoring System Market 

5.1. COVID-19 Landscape: Non-Invasive Blood Glucose Monitoring System Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Non-Invasive Blood Glucose Monitoring System Market, By Technology

8.1. Non-Invasive Blood Glucose Monitoring System Market, by Technology, 2024-2034

8.1.1. Spectroscopy

8.1.1.1. Market Revenue and Forecast (2021-2034)

8.1.2. Electromagnetic

8.1.2.1. Market Revenue and Forecast (2021-2034)

8.1.3. Microwave

8.1.3.1. Market Revenue and Forecast (2021-2034)

8.1.4. Ultrasonic

8.1.4.1. Market Revenue and Forecast (2021-2034)

8.1.5. Thermal

8.1.5.1. Market Revenue and Forecast (2021-2034)

8.1.6. Others

8.1.6.1. Market Revenue and Forecast (2021-2034)

Chapter 9. Global Non-Invasive Blood Glucose Monitoring System Market, By End User

9.1. Non-Invasive Blood Glucose Monitoring System Market, by End User, 2024-2034

9.1.1. Others

9.1.1.1. Market Revenue and Forecast (2021-2034)

9.1.2. Homecare

9.1.2.1. Market Revenue and Forecast (2021-2034)

9.1.3. Homecare

9.1.3.1. Market Revenue and Forecast (2021-2034)

Chapter 10. Global Non-Invasive Blood Glucose Monitoring System Market, By Modality 

10.1. Non-Invasive Blood Glucose Monitoring System Market, by Modality, 2024-2034

10.1.1. Homecare

10.1.1.1. Market Revenue and Forecast (2021-2034)

10.1.2. Homecare

10.1.2.1. Market Revenue and Forecast (2021-2034)

10.1.3. Invasive

10.1.3.1. Market Revenue and Forecast (2021-2034)

10.1.4. Non-invasive

10.1.4.1. Market Revenue and Forecast (2021-2034)

Chapter 11. Global Non-Invasive Blood Glucose Monitoring System Market, By Distribution Channel 

11.1. Non-Invasive Blood Glucose Monitoring System Market, by Distribution Channel, 2024-2034

11.1.1. Retail sales

11.1.1.1. Market Revenue and Forecast (2021-2034)

11.1.2. Institutional sales

11.1.2.1. Market Revenue and Forecast (2021-2034)

Chapter 12. Global Non-Invasive Blood Glucose Monitoring System Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Technology (2021-2034)

12.1.2. Market Revenue and Forecast, by End User (2021-2034)

12.1.3. Market Revenue and Forecast, by Modality (2021-2034)

12.1.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Technology (2021-2034)

12.1.5.2. Market Revenue and Forecast, by End User (2021-2034)

12.1.5.3. Market Revenue and Forecast, by Modality (2021-2034)

12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Technology (2021-2034)

12.1.6.2. Market Revenue and Forecast, by End User (2021-2034)

12.1.6.3. Market Revenue and Forecast, by Modality (2021-2034)

12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Technology (2021-2034)

12.2.2. Market Revenue and Forecast, by End User (2021-2034)

12.2.3. Market Revenue and Forecast, by Modality (2021-2034)

12.2.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Technology (2021-2034)

12.2.5.2. Market Revenue and Forecast, by End User (2021-2034)

12.2.5.3. Market Revenue and Forecast, by Modality (2021-2034)

12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Technology (2021-2034)

12.2.6.2. Market Revenue and Forecast, by End User (2021-2034)

12.2.6.3. Market Revenue and Forecast, by Modality (2021-2034)

12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Technology (2021-2034)

12.2.7.2. Market Revenue and Forecast, by End User (2021-2034)

12.2.7.3. Market Revenue and Forecast, by Modality (2021-2034)

12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Technology (2021-2034)

12.2.8.2. Market Revenue and Forecast, by End User (2021-2034)

12.2.8.3. Market Revenue and Forecast, by Modality (2021-2034)

12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Technology (2021-2034)

12.3.2. Market Revenue and Forecast, by End User (2021-2034)

12.3.3. Market Revenue and Forecast, by Modality (2021-2034)

12.3.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Technology (2021-2034)

12.3.5.2. Market Revenue and Forecast, by End User (2021-2034)

12.3.5.3. Market Revenue and Forecast, by Modality (2021-2034)

12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Technology (2021-2034)

12.3.6.2. Market Revenue and Forecast, by End User (2021-2034)

12.3.6.3. Market Revenue and Forecast, by Modality (2021-2034)

12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Technology (2021-2034)

12.3.7.2. Market Revenue and Forecast, by End User (2021-2034)

12.3.7.3. Market Revenue and Forecast, by Modality (2021-2034)

12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Technology (2021-2034)

12.3.8.2. Market Revenue and Forecast, by End User (2021-2034)

12.3.8.3. Market Revenue and Forecast, by Modality (2021-2034)

12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Technology (2021-2034)

12.4.2. Market Revenue and Forecast, by End User (2021-2034)

12.4.3. Market Revenue and Forecast, by Modality (2021-2034)

12.4.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Technology (2021-2034)

12.4.5.2. Market Revenue and Forecast, by End User (2021-2034)

12.4.5.3. Market Revenue and Forecast, by Modality (2021-2034)

12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Technology (2021-2034)

12.4.6.2. Market Revenue and Forecast, by End User (2021-2034)

12.4.6.3. Market Revenue and Forecast, by Modality (2021-2034)

12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Technology (2021-2034)

12.4.7.2. Market Revenue and Forecast, by End User (2021-2034)

12.4.7.3. Market Revenue and Forecast, by Modality (2021-2034)

12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Technology (2021-2034)

12.4.8.2. Market Revenue and Forecast, by End User (2021-2034)

12.4.8.3. Market Revenue and Forecast, by Modality (2021-2034)

12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Technology (2021-2034)

12.5.2. Market Revenue and Forecast, by End User (2021-2034)

12.5.3. Market Revenue and Forecast, by Modality (2021-2034)

12.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Technology (2021-2034)

12.5.5.2. Market Revenue and Forecast, by End User (2021-2034)

12.5.5.3. Market Revenue and Forecast, by Modality (2021-2034)

12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Technology (2021-2034)

12.5.6.2. Market Revenue and Forecast, by End User (2021-2034)

12.5.6.3. Market Revenue and Forecast, by Modality (2021-2034)

12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

Chapter 13. Company Profiles

13.1. Abbott Laboratories

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Medtronic plc

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. F. Hoffmann-La Roche Ltd.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Ascensia Diabetes Care

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Dexcom, Inc.

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Sanofi Novo Nordisk

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Abbott

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Ypsomed Holdings

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Glysens Incorporated

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client